Geovax Domain Overviewđź”’ SSL Verified
Live Data Status: |News & Media
Welcome to the detailed analysis for geovax.com. This domain is officially recognized as Home - GeoVax, Inc.. According to their official web presence, their primary focus is: "Aids Vaccine Research - GeoVax, Inc.".
Table of Contents
- Tech Stack
- Custom Built / Unknown
- Link Profile
- Internal Pages: 65Outbound Links: 5
- Localization
- en
6-Month Traffic Trend Estimate
M1
M2
M3
M4
M5
M6
Estimated Market Value
$15,400
Based on domain age, authority, and keyword relevance.
TLD Availability Risk
- geovax.comTaken
- geovax.netTaken
- geovax.orgTaken
- geovax.ioTaken
- geovax.coTaken
- geovax.aiAvailable
Content Snippets from geovax.com
"GeoVax Labs, Inc. is a clinical-stage biotechnology company focused on the development of vaccines and immunotherapies addressing high-consequence infectious diseases and solid tumor cancers."
"GeoVax’s near-term development priority is GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. GEO-MVA is being advanced on an expedited regulatory pathway provided by the European Medicines Agency ("EMA", the European equivalent of the FDA) and is intended to address a significant global supply constraint for MVA vaccine. The Company believes GEO-MVA is well-positioned to support both civilian public health needs and broader preparedness and biodefense objectives. GEO-MVA represents a near-term potential opportunity to achieve regulatory approval and subsequent commercialization. Plans include initiation of a pivotal Phase 3 clinical trial in Fourth Quarter of 2026."
"In addition to GEO-MVA, GeoVax’s clinical development programs include Gedeptin®, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. A Phase 2 clinical trial evaluating Gedeptin® in combination with an immune checkpoint inhibitor (ICI) as first-line treatment of patients with squamous cell head and neck cancer eligible for curative surgery, is planned to initiate during the second half of 2027."
"Additional research and development programs include preventive vaccines against hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, and Marburg)."
Key Topics & Focus Areas for geovax.com:
Authority Metrics: Score 95/100
Global Reach of Geovax
Competitor Analysis for .COM Domains
By comparing geovax.com to other leading websites in its niche, marketers and researchers can identify key traffic sources and growth opportunities. Explore our related resources below to find websites similar to geovax.com.
Frequently Asked Questions
Is geovax.com a safe and secure website?
Yes, according to our latest analysis, we detected a valid SSL certificate ensuring a secure connection.
What is the authority score of geovax.com?
As of August 15, 2026, geovax.com holds an estimated domain authority score of 70/100 based on our VisitRank tracking algorithms.
What are the top alternatives to geovax.com?
You can find the best alternatives and similar sites to geovax.com in our explore section, which includes competitors in the News & Media sector.
Data Sources & Methodology: DNS telemetry and routing records are resolved via live root servers. Market valuation estimates are computed algorithmically based on proprietary historical indexation multiples and standardized digital asset appraisal methodologies.
Common Misspellings & Typo Domains for geovax.com:
goevax.comgevax.comgeeovax.comgaovax.comgeovax.comgeovex.comgwovax.comgsovax.com